|
BL22 Immunotoxin to Treat Hairy Cell Leukemia Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about BL22 Immunotoxin to Treat Hairy Cell Leukemia conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. BL22 Immunotoxin to Treat Hairy Cell Leukemia Clinical research trials and BL22 Immunotoxin to Treat Hairy Cell Leukemia health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as BL22 Immunotoxin to Treat Hairy Cell Leukemia. BL22 Immunotoxin to Treat Hairy Cell Leukemia Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a BL22 Immunotoxin to Treat Hairy Cell Leukemia clinical trial. Human subjects frequently get the finest healthcare available for their BL22 Immunotoxin to Treat Hairy Cell Leukemia condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > BL22 Immunotoxin to Treat Hairy Cell Leukemia  BL22 Immunotoxin to Treat Hairy Cell Leukemia
BL22 Immunotoxin to Treat Hairy Cell Leukemia
For Condition: Leukemia, Hairy Cell
Status: Recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: This study will examine the safety and effectiveness of the experimental drug BL22 for treating hairy cell leukemia. BL22 can kill leukemia cells that have a protein on their surface called CD22. The drug is made up of two parts - a protein that binds to the CD22 protein on a cancer cell and a toxin (type of poison) that kills the cancer cell to which it binds. In a preliminary study of BL22 in patients with leukemias and lymphomas, several patients with hairy cell leukemia have achieved disease remission ranging from 6 to 43 months. Patients 18 years of age and older with hairy cell leukemia whose cancer cells have the CD22 protein may be eligible for this study. Candidates will be screened with a medical history and physical examination, blood tests, electrocardiogram (EKG), chest x-ray, and bone marrow biopsy. Participants will undergo the following tests and procedures: - BL22 treatment: BL22 is given by intravenous (through a vein) infusion over 30 minutes on days 1, 3, and 5 of each 4-week treatment cycle. The drug is infused through a central venous catheter (plastic tube placed in a large vein). The first infusion is given on an inpatient basis, with subsequent cycles given as outpatients. Acetaminophen, ranitidine, and hydroxyzine are given around the time of the BL22 infusion to reduce the risk of an allergic reaction to the drug. Other treatments, such as transfusions and antibiotics, are given if required. Patients are evaluated 8 weeks after the first cycle. Those whose blood counts improve to a certain level are observed without further treatment. Others may receive up to 9 nine additional cycles of BL22 every 4 weeks unless the disease worsens, serious side effects develop, or the patient decides to withdraw from the study. - Blood tests: A small amount of blood is drawn before, during, and after each treatment cycle to measure the amount of BL22 in the blood, the effects of the drug on cancer cells in the blood, and to monitor for drug side effects. Blood tests are also done before and during each cycle to assess the immune system response to BL22. - Disease progress is evaluated before each cycle and at follow-up visits. These evaluations include a physical examination, blood tests, chest x-ray, and electrocardiogram (EKG). Bone marrow biopsy, computed tomography (CT) scan, and echocardiogram (heart ultrasound test) are done before starting the first treatment cycle and after every two cycles, or more often if they contribute to an understanding of how the leukemia is reacting to BL22.
Details: The purpose of this study is to determine the activity of BL22 in patients with cladribine-resistant Hairy Cell Leukemia (HCL). All leukemic hairy cells intensely express CD22, a membrane protein associated with B cell signaling. BL22 is an anti-CD22 recombinant immunotoxin containing the variable domains of MAb RFB4 (anti-CD22) and truncated Pseudomonas exotoxin. A phase I trial of BL22 at NCI demonstrated that patients with cladribine-resistant HCL had a high response rate to BL22. Of the first 25 HCL patients, 18 had complete remissions and 2 had partial remissions. Those who did not respond had received lower doses of BL22, developed neutralizing antibodies against BL22, or had bulky lymphadenopathy. The dose limiting toxicity was hemolytic uremic syndrome in 5 patients. Four of these patients had HCL and recovered completely. All 4 had clinical benefit and 3 went into complete remissions. An additional 6 patients were enrolled at a lower dose (30 micro g/Kg IV given every other day for 3 doses (QOD x 3) on cycle 1 and 20 micro g/Kg on cycles 2-5) and treated every 6 weeks (instead of every 3-4 weeks). Of these 6 patients, none had dose limiting toxicity and 1 had a CR. The primary endpoint of this phase II trial is to determine the response rate of cladribine-resistant HCL patients to BL22. We will also evaluate response duration, BL22 immunogenicity, blood levels of BL22, and toxicity.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: 1. Histopathological evidence of CD22+ HCL confirmed by the NIH pathology department. This will require a monoclonal population of peripheral malignant lymphocytes that are CD22 positive by fluorescence activated cell sorting (FACS) with anti-CD22 antibody. Positive expression in a FACS assay is defined as more than 2 times the mean fluorescence intensity (MFI) of the control antibody by FACS. 2. At least one of the following indications for treatment: neutropenia (ANC less than 1000 cells/ul), anemia (Hgb less than 10g/dL), thromobocytopenia (Plt less than 100,000/ul), an absolute lymphocyte count of greater than 20,000 cells/ul, or symptomatic splenomegaly. 3. No response or less than a 2 year duration of CR or PR after the last course of cladribine. 4. ECOG performance status of 0-2. 5. At least 18 years old. 6. Understand and give informed consent. 7. A negative pregnancy test in female patients of childbearing potential. Women must not be breast-feeding. 8. ALT and AST less than or equal to 2.5 times the upper limits of normal. Albumin greater than or equal to 3.0 gm/dL. Total bilirubin less than or equal to 2.2mg/dL. 9. Creatinine less than or equal to 1.4 mg/dL or creatinine clearance greater than or equal to 50 ml/min. 10. Serum that neutralizes less than or equal to 75% of the activity of 1 micro g/mL of BL22 using a bioassay. 11. No systemic cytotoxic chemotherapy within 4 weeks of enrollment or systemic steroids (except stable doses of Prednisone less than or equal to 20 mg/day) within 4 weeks of enrollment. 12. No monoclonal antibody therapy within 12 weeks of enrollment. 13. No prior treatment with BL22. 14. Patients may not be receiving any other investigational agents. 15. Hepatitis B surface antigen negative. 16. Patients should not have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Total Enrollment: 25
Location and Contact Information:
National Cancer Institute (NCI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 040014; 04-C-0014
Study Start Date: October 15, 2003
Record last reviewed: February 3, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00071318
Other Leukemia, Hairy Cell Studies:
1. BL22 Immunotoxin to Treat Hairy Cell Leukemia
Related Studies:
Other Leukemia, Hairy Cell Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
BL22 Immunotoxin to Treat Hairy Cell Leukemia
|
|
|
|
|
|
|
|
